Hyderabad: Hyderabad-based specialty biopharmaceutical manufacturer, Celon Laboratories, launched an alternative drug-Amphotericin B Emulsion, for the treatment of Mucormycosis, commonly known as Black Fungus. The drug is set to be made available in the market from next Monday onwards.
Amphotericin B is crucial to the treatment of Mucormycosis, of which a sudden resurgence is being witnessed off late among Covid-19 patients, across India. Though Celon has been manufacturing Liposomal Amphotericin B since 2013, market demands were not met due to the unavailability of a critical ingredient sourced from Germany— lipoids.
To bypass the bottleneck caused by this sourcing obstacle and increase production of this medication, Celon developed an alternative, an emulsion-based formulation. The drug whose pricing is not yet revealed, uses Amphotericin B as a bulk drug besides soybean oil, egg lecithin and glycerin.
Exhaustively developed by Celon’s in-house R & D team in a record three weeks, the emulsion-based formulation will provide hospitals and Covid-19 treatment centres with increased resources to treat the Black Fungus.
Celon will manufacture 10,000 vials per day, which will ensure relief for approximately 6,000 patients monthly.
Celon Labs’ MD M Nagesh Kumar, said, “The emulsion-based formulation is an ideal alternative to Liposomal Amphotericin B to combat the Black Fungus. The company will start supplying to the domestic market soon.”
Now you can get handpicked stories from Telangana Today onTelegrameveryday. Click the link to subscribe.